(VIANEWS) – Zynex (ZYXI), Reinsurance Group of America (RGA), Universal Display Corporation (OLED) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Zynex (ZYXI)
20.7% sales growth and 16.75% return on equity
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, Zynex has a trailing twelve months EPS of $0.23.
PE Ratio
Zynex has a trailing twelve months price to earnings ratio of 44.74. Meaning, the purchaser of the share is investing $44.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.75%.
Yearly Top and Bottom Value
Zynex’s stock is valued at $10.29 at 06:22 EST, way under its 52-week high of $13.77 and way above its 52-week low of $6.88.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 11.1% and positive 60% for the next.
Sales Growth
Zynex’s sales growth is 15.9% for the current quarter and 20.7% for the next.
Volume
Today’s last reported volume for Zynex is 258061 which is 97.95% above its average volume of 130362.
2. Reinsurance Group of America (RGA)
18.4% sales growth and 10.05% return on equity
Reinsurance Group of America, Incorporated engages in reinsurance business. The company offers individual and group life and health insurance products, such as term life, credit life, universal life, whole life, group life and health, joint and last survivor insurance, critical illness, disability, and longevity products; asset-intensive and financial reinsurance products; and other capital motivated solutions. It also provides reinsurance for mortality, morbidity, lapse, and investment-related risk associated with products; and reinsurance for investment-related risks. In addition, the company develops and markets technology solutions; and provides consulting and outsourcing solutions for the insurance and reinsurance industries. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1973 and is headquartered in Chesterfield, Missouri.
Earnings Per Share
As for profitability, Reinsurance Group of America has a trailing twelve months EPS of $12.89.
PE Ratio
Reinsurance Group of America has a trailing twelve months price to earnings ratio of 15.81. Meaning, the purchaser of the share is investing $15.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.05%.
3. Universal Display Corporation (OLED)
16.6% sales growth and 15.8% return on equity
Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. It owns, exclusively licenses, or has sole rights to sublicense approximately 5,500 issued and pending patents worldwide. The company supplies its proprietary UniversalPHOLED materials to display and lighting manufacturers, and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; OVJP, an organic vapor jet printing technology; thin-film encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates; and UniversalP2OLED, which are printable phosphorescent OLEDs. In addition, the company provides technology development and support services, including third-party collaboration and support to third parties for the commercialization of their OLED products. Further, it provides contract research services in the areas of chemical materials synthesis research, development, and commercialization for non-OLED applications. Universal Display Corporation was founded in 1985 and is headquartered in Ewing, New Jersey.
Earnings Per Share
As for profitability, Universal Display Corporation has a trailing twelve months EPS of $4.61.
PE Ratio
Universal Display Corporation has a trailing twelve months price to earnings ratio of 48.08. Meaning, the purchaser of the share is investing $48.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.8%.
Sales Growth
Universal Display Corporation’s sales growth is 23.9% for the current quarter and 16.6% for the next.
Moving Average
Universal Display Corporation’s worth is way higher than its 50-day moving average of $188.31 and way higher than its 200-day moving average of $172.83.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.7%, now sitting on 611.22M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 8.7% and 9.3%, respectively.
4. Celestica (CLS)
12.1% sales growth and 19.1% return on equity
Celestica Inc. provides hardware platform and supply chain solutions in North America, Europe, and Asia. It operates through two segments, Advanced Technology Solutions, and Connectivity & Cloud Solutions. The company offers a range of product manufacturing and related supply chain services, including design and development, engineering, supply chain management, new product introduction, component sourcing, electronics manufacturing and assembly, testing, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics, asset management, product licensing, and after-market repair and return services. It also provides enterprise-level data communications and information processing infrastructure products, such as routers, switches, data center interconnects, servers, and storage-related products; capacitors, microprocessors, resistors, and memory modules; and power inverters, energy storage products, smart meters, and other electronic componentry. The company serves aerospace and defense, industrial, energy, healthtech, capital equipment, original equipment manufacturers (OEMs), cloud-based, and other service providers, including hyperscalers, and other companies in a range of industries. Celestica Inc. was incorporated in 1994 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Celestica has a trailing twelve months EPS of $2.68.
PE Ratio
Celestica has a trailing twelve months price to earnings ratio of 21.08. Meaning, the purchaser of the share is investing $21.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.1%.
Sales Growth
Celestica’s sales growth is 15.9% for the ongoing quarter and 12.1% for the next.
Moving Average
Celestica’s value is higher than its 50-day moving average of $55.58 and way higher than its 200-day moving average of $39.85.
Previous days news about Celestica(CLS)
- Is celestica (cls) stock a smart buy ahead of Q2 earnings?. According to Zacks on Friday, 19 July, "During the quarter, Celestica inked a definitive agreement to acquire NCS Global Services LLC, a prominent IT infrastructure and asset manager business in the United States for $36 million. ", "With a comprehensive and diversified product portfolio, Celestica has been capitalizing on the growing proliferation of AI-based applications and generative AI tools across industries. "
5. PulteGroup (PHM)
9.9% sales growth and 27.3% return on equity
PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, American West, and John Wieland Homes and Neighborhoods brand names. As of December 31, 2022, it controlled 211,112 lots, of which 108,848 were owned and 102,264 were under land option agreements. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was founded in 1950 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, PulteGroup has a trailing twelve months EPS of $12.47.
PE Ratio
PulteGroup has a trailing twelve months price to earnings ratio of 8.3. Meaning, the purchaser of the share is investing $8.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.3%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 18, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.76%.
Volume
Today’s last reported volume for PulteGroup is 197689 which is 88.69% below its average volume of 1749360.
Previous days news about PulteGroup(PHM)
- Pultegroup (phm) stock before Q2 earnings: buy, sell, or hold?. According to Zacks on Friday, 19 July, "In the first quarter of 2024, PulteGroup demonstrated strong resilience in a high-rate environment. ", "Despite market challenges, PulteGroup saw a 14% rise in net orders, increased net pricing in half of its communities, and achieved a record first-quarter gross margin of 29.6%, exceeding guidance."
6. Horace Mann Educators Corporation (HMN)
9.4% sales growth and 5.52% return on equity
Horace Mann Educators Corporation, together with its subsidiaries, operates as an insurance holding company in the United States. It operates in three segments: Property & Casualty, Life & Retirement, and Supplemental & Group Benefits. The company underwrites and markets personal lines of property and casualty insurance, including personal lines auto and property insurance products; supplemental insurance products, which include cancer, heart, hospital, supplemental disability, and accident coverages; retirement products, such as tax-qualified fixed and variable annuities; and life insurance products comprising whole life and term, as well as indexed universal life insurance products. It also offers student loan solutions, including online student loan management accounts for educators. The company markets its products through its sales force of full-time exclusive agents to K-12 teachers, administrators, and other employees of public schools and their families. Horace Mann Educators Corporation was founded in 1945 and is headquartered in Springfield, Illinois.
Earnings Per Share
As for profitability, Horace Mann Educators Corporation has a trailing twelve months EPS of $1.57.
PE Ratio
Horace Mann Educators Corporation has a trailing twelve months price to earnings ratio of 21.8. Meaning, the purchaser of the share is investing $21.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.52%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 13, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 3.97%.
Volume
Today’s last reported volume for Horace Mann Educators Corporation is 208618 which is 17.74% below its average volume of 253616.
7. Grifols, S.A. (GRFS)
9.1% sales growth and 3.48% return on equity
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Earnings Per Share
As for profitability, Grifols, S.A. has a trailing twelve months EPS of $0.1.
PE Ratio
Grifols, S.A. has a trailing twelve months price to earnings ratio of 84.45. Meaning, the purchaser of the share is investing $84.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
Yearly Top and Bottom Value
Grifols, S.A.’s stock is valued at $8.44 at 06:22 EST, way under its 52-week high of $12.15 and way above its 52-week low of $5.30.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 6.66B for the twelve trailing months.
Moving Average
Grifols, S.A.’s value is way higher than its 50-day moving average of $7.04 and above its 200-day moving average of $8.05.
8. Synopsys (SNPS)
8.4% sales growth and 21.58% return on equity
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $9.04.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 61.63. Meaning, the purchaser of the share is investing $61.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.58%.
Volume
Today’s last reported volume for Synopsys is 796977 which is 35.19% below its average volume of 1229830.
Yearly Top and Bottom Value
Synopsys’s stock is valued at $557.16 at 06:22 EST, way under its 52-week high of $629.38 and way higher than its 52-week low of $418.51.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 6.31B for the twelve trailing months.
